The Oncolytic Edge: Advancing Cancer Therapies with Viral Vectors

MilliporeSigma is the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany.

Join our virtual symposium where we delve into the transformative potential of oncolytic viruses as innovative immunotherapeutic agents.

What you will learn:

• Engineering techniques for targeted delivery by oncolytic viruses.
• Combining oncolytic viruses with other immunotherapies.
• Translating preclinical findings to clinical applications.

Dr. Christene Engeland's talk on Immunotherapeutics:

Oncolytic viruses are a promising class of immunotherapeutics. As versatile engineering platforms, they can be harnessed for tumor-targeted delivery of cell engagers and cytokines.

Rational combinations with immune checkpoint blockade and cellular therapies are emerging as novel treatment strategies. This talk will highlight recent preclinical developments and translational research in this field.